Cardiac disease in pregnancy and valvular heart disease: Difference between revisions

Jump to navigation Jump to search
(/* Prosthetic Valves and Pregnancy{{cite journal| author=Elkayam U, Singh H, Irani A, Akhter MW| title=Anticoagulation in pregnant women with prosthetic heart valves. | journal=J Cardiovasc Pharmacol Ther | year= 2004 | volume= 9 | issue= 2 | pages=)
Line 37: Line 37:


===Mechanical Prosthetic Valves===
===Mechanical Prosthetic Valves===
Mechanic valves can be problematic in pregnancy, due to the requirement of anticoagulation.  Regardless of the strategy used, there is a higher chance of fetal loss, placental hemorrhage, and prosthetic valve thrombosis.
Recommendations from the ACC/AHA for anticoagulation during pregnancy are:<ref name="pmid16053950">{{cite journal| author=Elkayam U, Bitar F| title=Valvular heart disease and pregnancy: part II: prosthetic valves. | journal=J Am Coll Cardiol | year= 2005 | volume= 46 | issue= 3 | pages= 403-10 | pmid=16053950 | doi=10.1016/j.jacc.2005.02.087 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16053950  }} </ref>
Recommendations from the ACC/AHA for anticoagulation during pregnancy are:<ref name="pmid16053950">{{cite journal| author=Elkayam U, Bitar F| title=Valvular heart disease and pregnancy: part II: prosthetic valves. | journal=J Am Coll Cardiol | year= 2005 | volume= 46 | issue= 3 | pages= 403-10 | pmid=16053950 | doi=10.1016/j.jacc.2005.02.087 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16053950  }} </ref>


Line 54: Line 57:


'''7.'''  In the absence of significant bleeding, heparin can be resumed 4–6 h after delivery, and warfarin begun orally.}}
'''7.'''  In the absence of significant bleeding, heparin can be resumed 4–6 h after delivery, and warfarin begun orally.}}
===Tissue Prosthetic Valves===
Tissue valves have less thrombogencity than mechanical valves.  As a result, they do not routinely involve the use of warfarin/anticoagulation.  For a more thorough discussion on tissue valves, click [[Artificial heart valve|here]].


==References==
==References==

Revision as of 21:07, 11 October 2011

Cardiac disease in pregnancy Microchapters

Home

Overview

Pathophysiology

Epidemiology and Demographics

Risk Factors

Diagnosis

History and Symptoms

Physical Examination

Electrocardiogram

Exercise Testing

Radiation Exposure

Chest X Ray

Echocardiography

MRI

CT

Catheterization:

Pulmonary artery catheterization
Cardiac catheterization
Cardiac Ablation

Treatment

Cardiovascular Drugs in Pregnancy

Labor and delivery

Resuscitation in Late Pregnancy

Contraindications to pregnancy

Special Scenarios:

I. Pre-existing Cardiac Disease:
Congenital Heart Disease
Repaired Congenital Heart Disease
Pulmonary Hypertension
Rheumatic Heart Disease
Connective Tissue Disorders
II. Valvular Heart Disease:
Mitral Stenosis
Mitral Regurgitation
Aortic Insufficiency
Aortic Stenosis
Mechanical Prosthetic Valves
Tissue Prosthetic Valves
III. Cardiomyopathy:
Dilated Cardiomyopathy
Hypertrophic Cardiomyopathy
Peripartum Cardiomyopathy
IV. Cardiac diseases that may develop During Pregnancy:
Arrhythmias
Acute Myocardial Infarction
Hypertension

Cardiac disease in pregnancy and valvular heart disease On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac disease in pregnancy and valvular heart disease

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac disease in pregnancy and valvular heart disease

CDC on Cardiac disease in pregnancy and valvular heart disease

Cardiac disease in pregnancy and valvular heart disease in the news

Blogs on Cardiac disease in pregnancy and valvular heart disease

Directions to Hospitals Treating Cardiac disease in pregnancy

Risk calculators and risk factors for Cardiac disease in pregnancy and valvular heart disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Anjan K. Chakrabarti, M.D. [2]

Overview

As previously mentioned, rheumatic heart disease remains prevalent in developing countries but is less common in Western countries; as a result Western countries see less mitral stenosis complicating pregnancy. Bicuspid aortic stenosis, mitral regurgitation, aortic regurgitation, and prosthetic valves can all be problematic during pregnancy due to physiologic hemodynamic changes.

For a general overview of valvular heart disease, click here.

Specific Issues with Valvular Disease in Pregnancy

Mitral Stenosis

  • Increase in cardiac output coupled with the increase in heart rate shortens the diastolic filling time
  • Tends to exaggerate the mitral valve gradient
  • Patients should have echocardiography prior to proceeding with pregnancy
  • Exercise echocardiography may be warranted
  • Judicious use of diuretics and beta-blockade are appropriate in symptomatic cases
  • Balloon valvuloplasty has been described in symptomatic cases[1]

Mitral Regurgitation

  • Fairly well tolerated in pregnancy
  • The left ventricle tends to dilate as pregnancy progresses, and this may worsen mitral regurgitation
  • Early delivery is sometimes necessary in case of maternal hemodynamic instability

Aortic Insufficiency

  • As with mitral regurgitation, fairly well tolerated
  • Closer monitoring is warranted, early delivery may be necessary

Aortic Stenosis

  • Generally due to bicuspid aortic valve
  • Moderate stenosis may be tolerated in a compliant patient who is monitored closely
  • Aortic root dilation > 4.5cm is a contraindication to pregnancy.
  • Balloon valvuloplasty has been safely performed in a small subset of pregnancy patients with some success, as described by Myerson et al.[2]

Prosthetic Valves and Pregnancy[3]

Mechanical Prosthetic Valves

Mechanic valves can be problematic in pregnancy, due to the requirement of anticoagulation. Regardless of the strategy used, there is a higher chance of fetal loss, placental hemorrhage, and prosthetic valve thrombosis.

Recommendations from the ACC/AHA for anticoagulation during pregnancy are:[4]

1. The decision whether to use heparin during the first trimester or to continue oral anticoagulation throughout pregnancy should be made after full discussion with the patient and her partner; if she chooses to change to heparin for the first trimester, she should be made aware that heparin is less safe for her, with a higher risk of both thrombosis and bleeding, and that any risk to the mother also jeopardizes the baby.

2. High-risk women (a history of thromboembolism or an older- generation mechanical prosthesis in the mitral position) who choose not to take warfarin during the first trimester should receive continuous unfractionated heparin intravenously in a dose to prolong the mid-interval (6 h after dosing) activated partial thromboplastin time to 2 to 3 x control value. Transition to warfarin can occur thereafter.

3. In patients receiving warfarin, the international normalized ratio should be maintained between 2.0 and 3.0 with the lowest possible dose of warfarin, and low-dose aspirin should be added.

4. Women at low risk (no history of thromboembolism, newer low- profile prosthesis) might be managed with adjusted-dose subcutaneous heparin (17,500 to 20,000 U twice daily to prolong the mid-interval (6 h after dosing) activated partial thromboplastin time to 2 to 3 x control value.

5. Warfarin should be stopped no later than week 36 and heparin substituted in anticipation of labor.

6. If labor begins during treatment with warfarin, a cesarean section should be performed.

7. In the absence of significant bleeding, heparin can be resumed 4–6 h after delivery, and warfarin begun orally.

Tissue Prosthetic Valves

Tissue valves have less thrombogencity than mechanical valves. As a result, they do not routinely involve the use of warfarin/anticoagulation. For a more thorough discussion on tissue valves, click here.

References

  1. Routray SN, Mishra TK, Swain S, Patnaik UK, Behera M (2004). "Balloon mitral valvuloplasty during pregnancy". Int J Gynaecol Obstet. 85 (1): 18–23. doi:10.1016/j.ijgo.2003.09.005. PMID 15050462.
  2. Myerson SG, Mitchell AR, Ormerod OJ, Banning AP (2005). "What is the role of balloon dilatation for severe aortic stenosis during pregnancy?". J Heart Valve Dis. 14 (2): 147–50. PMID 15792172.
  3. Elkayam U, Singh H, Irani A, Akhter MW (2004). "Anticoagulation in pregnant women with prosthetic heart valves". J Cardiovasc Pharmacol Ther. 9 (2): 107–15. PMID 15309247.
  4. Elkayam U, Bitar F (2005). "Valvular heart disease and pregnancy: part II: prosthetic valves". J Am Coll Cardiol. 46 (3): 403–10. doi:10.1016/j.jacc.2005.02.087. PMID 16053950.


Template:WH Template:WS